Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Solon Eiendom ASA : Q1 2018 - Record results

Solon Eiendom ASA
Posted on: 16 May 18
 

Solon Eiendom's revenues (IFRS) increased to NOK 489 million in Q1 2018 compared to NOK 225 million in Q1 2017. EBITDA (IFRS) increased to NOK 117 million, compared to NOK 33 million in Q1 2017.

"Q1 2018 has been a very strong quarter for Solon Eiendom with three successful sales starts. In addition, we have doubled our revenues and more than tripled EBITDA compared to the same quarter last year," says CEO Andreas Martinussen.

Highlights for Q1 2018 (Q1 2017 in brackets)

- NGAAP: Operating revenues of NOK 366 million (NOK 170 million), EBITDA of NOK 83 million (NOK 26 million)

- IFRS: Operating revenues of NOK 489 million (NOK 225 million), EBITDA of NOK 117 million (NOK 33 million)

- 189 (236) homes under construction at the end of the quarter, of which 89 % (87 %) were sold for a total sales value of NOK 1,343 million (NOK 1,222 million)

- 95 % of homes to be completed in 2018 have already been sold

This information is subject to the disclosure requirements set out in section 5-12 of the Norwegian Securities Trading Act.

Further information
Andreas Martinussen
Chief Executive Officer, Solon Eiendom ASA
E-mail: am@soloneiendom.no Cell Phone: +47 400 00 405

Scott Danielsen
Chief Financial Officer, Solon Eiendom ASA
E-mail: sd@soloneiendom.no Cell Phone: +47 952 55 620

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region.

SEA20180516_SOLON_Q1_2018_Markedspresentasjon
SEA20180516_SOLON_Q1_2018_Presentation
SEA20180516_SOLON_Q1_2018_Kvartalsrapport


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Solon Eiendom ASA via GlobeNewswire
HUG#2192818
GlobeNewswire
globenewswire.com

Last updated on: 17/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.